Clinical Trial Update: All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the combination of All-Trans Retinoic Acid (ATRA) with a PD-1 inhibitor in recurrent IDH-mutant glioma; recruiting is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioma
• Idh-mutant Glioma
• Oligodendroglioma

Drugs mentioned

• All-trans retinoic acid (ATRA) (all-trans retinoic acid)
• PD-1 inhibitor

Snippet

Sponsor: Stephen Bagley, MD, MSCE | Conditions: Glioma, IDH Mutation | Phase 2 | Status: RECRUITING